Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...
Investors looking for stocks in the Oil and Gas - Exploration and Production - United States sector might want to consider either Venture Global (VG Quick Quote VG - Free Report) or Cheniere Energy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results